Cathy Eng, MD

Articles

Dr. Eng on Future Research Efforts in Adjuvant CRC

December 21st 2020

Cathy Eng, MD, FACP, FASCO, discusses future research efforts in the adjuvant setting for colorectal cancer.

Dr. Eng on the Role of Preventive Screening in CRC

November 19th 2020

Cathy Eng, MD, FACP, FASCO, discusses the role of ​preventive screening in colorectal cancer.

Dr. Eng on Contraindications for Oxaliplatin-Based Therapy in CRC

November 19th 2020

Cathy Eng, MD, FACP, FASCO, discusses ​contraindications for oxaliplatin-based therapy in colorectal cancer.

Charting the Course for Patients With High-Risk Colon Cancer: 3 Months Versus 6 Months

November 19th 2020

In 5 years, it is estimated that approximately 20% of patients with stage II disease and 35% with stage III disease will experience disease recurrence. These estimates highlight the need to pursue progress in adjuvant systemic therapy in order to decrease recurrence rates and improve survival.

Dr. Eng Discusses the BEACON CRC Study in BRAF-Mutated CRC

April 17th 2019

Cathy Eng, MD, professor of gastrointestinal and medical oncology, Department of Gastrointestinal Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses the BEACON CRC study in patients with BRAF-mutated colorectal cancer.

Dr. Eng on Recognizing Tumor Sidedness in mCRC

February 23rd 2019

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses recognizing tumor sidedness in the treatment of patients with metastatic colorectal cancer.

Dr. Eng on the Treatment Landscape in Metastatic Colorectal Cancer

February 13th 2019

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the treatment landscape in newly diagnosed metastatic colorectal cancer (mCRC).

Dr. Eng Discusses the ADORE Trial in Rectal Cancer

September 19th 2018

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the ADORE trial in patients with rectal cancer.

Dr. Eng Discusses Results of the PRODIGE 7 Trial

July 23rd 2018

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses why the negative results of the PRODIGE 7 trial are beneficial moving forward.

Dr. Eng on the FDA Approval of Nivolumab Plus Ipilimumab in CRC

July 11th 2018

Cathy Eng, MD, professor of gastrointestinal medical oncology, The University of Texas MD Anderson Cancer Center, discusses the FDA approval of nivolumab (Opdivo) plus ipilimumab (Yervoy) in patients with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (mCRC) following progression on a fluoropyrimidine, oxaliplatin, and irinotecan.

x